Advanced search
Publication Cover
OncoImmunology Volume 10, 2021 - Issue 1
Submit an article Journal homepage
2,817
Views
11
CrossRef citations to date
0
Altmetric
Review

Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysis.

Alberto Carretero-Gonzáleza Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain
,
Irene Oterob Medical Oncology Department, Virgen de la Salud Hospital, Toledo, Spain
,
David Lorac Clinical Research Unit, IMAS12-CIBERESP, University Hospital 12 de Octubre, Madrid, Spain
,
Lucía Carril-Ajuriaa Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain
,
Daniel Castellanoa Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain
&
Guillermo de Velascoa Medical Oncology Department, University Hospital 12 de Octubre, Madrid, SpainCorrespondence[email protected]
Article: 1878599 | Received 18 Nov 2020, Accepted 15 Jan 2021, Published online: 23 Feb 2021

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Killian Carnet Le Provost, Oliver Kepp, Guido Kroemer & Lucillia Bezu. (2023) Trial watch: beta-blockers in cancer therapy. OncoImmunology 12:1.
Read now
Adriana Petrazzuolo, M. Chiara Maiuri, Laurence Zitvogel, Guido Kroemer & Oliver Kepp. (2022) Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy. OncoImmunology 11:1.
Read now

Articles from other publishers (9)

Pei Zhang, Lingli Zhang, Kai Xu, Yingtao Lin, Rui Ma, Mengdie Zhang & Xin Li. (2024) Evaluating the impact of PD-1 inhibitor treatment on key health outcomes for cancer patients in China. International Journal of Clinical Pharmacy 46:2, pages 429-438.
Crossref
Maria Maddalena Nicoletti, Erminia Crisci, Vincenzo Cosenza, Consiglia Riccardi, Maria Rosaria Campitiello, Donatella Ruggiero, Pasquale Maria Berrino, Giovanni Docimo & Cristina Scavone. (2023) Immune Checkpoint Inhibitors and Scleroderma: Data from the European Pharmacovigilance Database. Drugs - Real World Outcomes 11:1, pages 33-41.
Crossref
Ibrahim Elmakaty, Ruba Abdo, Ahmed Elsabagh, Abdelrahman Elsayed & Mohammed Imad Malki. (2023) Comparative efficacy and safety of PD-1/PD-L1 inhibitors in triple negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials. Cancer Cell International 23:1.
Crossref
Ai Sato, Jeffrey Kraynak, Ariel E. Marciscano & Lorenzo Galluzzi. 2023. Radiation Oncology and Radiotherapy Part C. Radiation Oncology and Radiotherapy Part C xv xxv .
Ai Sato, Jeffrey Kraynak, Ariel E. Marciscano & Lorenzo Galluzzi. 2023. Radiation Oncology and Radiotherapy. Radiation Oncology and Radiotherapy xv xxv .
Yiqun Han, Jiayu Wang, Yun Wu, Hangcheng Xu, Yan Wang & Binghe Xu. (2022) Optimal Choice as First-Line Therapy for Patients with Triple-Negative Breast Cancer: A Bayesian Network Meta-Analysis. Current Oncology 29:12, pages 9172-9180.
Crossref
Ai Sato, Jeffrey Kraynak, Ariel E. Marciscano & Lorenzo Galluzzi. 2022. Radiation Oncology and Radiotherapy Part A. Radiation Oncology and Radiotherapy Part A xiii xxiii .
Yueqin Sun, Qi Yang, Jie Shen, Ting Wei, Weitao Shen, Nan Zhang, Peng Luo & Jian Zhang. (2021) The Effect of Smoking on the Immune Microenvironment and Immunogenicity and Its Relationship With the Prognosis of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer. Frontiers in Cell and Developmental Biology 9.
Crossref
Yuki Uchihara, Tiara Bunga Mayang Permata, Hiro Sato & Atsushi Shibata. (2021) Modulation of immune responses by DNA damage signaling. DNA Repair 104, pages 103135.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.